Expert guides on supplement manufacturing, FDA compliance, cost optimization, and scaling your CPG business.
A 9-section mock recall simulation checklist covering scenario definition, raw material and production traceability, finished goods disposition, customer shipment mapping, response time documentation, gap analysis, and QA sign-off archiving. Designed for supplement, cosmetics, food, and CPG manufacturers running FSMA 204-aligned recall drills.
A 15-point inspection checklist for every raw material delivery, covering identity and integrity verification, COA potency deep-dives, FSMA 204 traceability logging, potency-based scaling triggers, and QA signature release. Includes the Potency Variance Loss framework and cross-references to the FSMA 204 Traceability Checklist.
A complete audit checklist and SOP for FSMA 204 compliance, covering the Digital Spine technical requirements, all three Critical Tracking Events (Receiving, Transformation, Shipping), a timed Stress Test for mock audits, and a ready-to-use Standard Operating Procedure for responding to an FDA 24-hour data request.
A complete manual for quality managers, covering how the Copilot applies 21 CFR Part 111, FSMA 204, and ISO 22716, a full ALCOA+ compliance map, a 20-prompt library, a 5-step pre-audit workflow, and an SOP template you can hand to an auditor.
A product recall is the moment your documentation infrastructure either protects your business or exposes it. This checklist walks you through the first 72 hours, the records you need to pull, stakeholder notifications, and the self-test that determines whether you can target one lot, or must pull your entire inventory.
Receiving an FDA Warning Letter triggers a public record, retailer alerts, and a strict response timeline. This guide walks you through the immediate 48-hour response, what documentation to pull, exactly what your formal response must contain, and a full pre-inspection documentation checklist to build now.
Data-backed insights from the front lines of formulation, compliance, and scale. `[NEEDS OWNER REVIEW: confirm sample size/methodology before final publish]` The report's benchmark data puts average raw material lead times at 81 days, outlines 3 commonly-missed MoCRA audit failure points, and finds AI-assisted labs cutting R&D cycles by up to 30% among surveyed facilities. Includes the Batch Health Index (BHI) framework for benchmarking your facility.
A Certificate of Analysis is the most-requested document in the hemp supply chain, but what retailers actually check goes well beyond a basic cannabinoid panel. Use this checklist before submitting to any retail buyer, marketplace, or certification program.
GLP-1 adjacent supplements are one of the most scrutinized categories in the current FDA enforcement environment. Audit your documentation practices against the standard an inspector or retail buyer would expect, before they do.
A practical breakdown of the 4 critical failure points that trigger FDA enforcement actions in 2026, from safety substantiation gaps to the 15-day adverse event clock. Includes a full MoCRA & GMP Readiness Checklist to benchmark your facility against current enforcement standards.
`[NEEDS OWNER REVIEW: confirm methodology/sourcing before final publish]` A deep dive into the financial architecture of Potency Variance Loss (PVL) and Batch Consistency ROI. Learn how a widely-cited ~88% spreadsheet error rate (a general spreadsheet-accuracy statistic, not a CPG-specific figure) illustrates how small errors compound into six-figure losses, and see the math behind potency-based scaling that can recover $500K–$1M in annual ingredient spend for manufacturers with comparable volume.
A practical self-assessment checklist that transforms complex 2026 FDA regulations into actionable Yes/No benchmarks. Score your facility across 5 phases, from facility registration and safety dossiers to post-market vigilance and ALCOA+ data integrity, and find out if you're Audit-Ready or Audit-Risky.
Monthly enforcement pattern analysis, pulled directly from FDA's public Warning Letter database as new letters post
A 25-letter telehealth sweep over compounded GLP-1 marketing, a sterility and data integrity failure at Wizcure Pharmaa, an "indication creep" device warning to BlephEx, and a wave of unauthorized-device citations. Four different mechanisms, one pattern: claims and processes drifting past what was actually validated -- and what locked MMRs, e-signature gates, and cryptographic audit trails do to stop it.
Two manufacturers. Two facilities. One in the U.S., one in Canada. Both received Warning Letters on the same day for the same two violations: failing to independently test incoming components and a quality unit that approved deficient specs without scrutiny. Here's what happened and what it means for your operation.
Being a contract manufacturer doesn't transfer your compliance obligations to the brand owner. This issue covers Asanuma Corporation's June 2026 Warning Letter -- the same component testing and quality unit failures as Issue 1, plus two things the others didn't have: a clear FDA position on contractor liability and an import alert that arrived before the Warning Letter was even issued.
Every issue covers real Warning Letters posted to the FDA public database — what the violations were, why they matter, and what to look for in your own operation.
All issues →Try BatchBuddy free for 14 days. No hidden fees, cancel anytime.
Start Free TrialLearn proven procurement strategies to reduce ingredient costs through direct sourcing, supplier qualification, and automated COA verification.
Try BatchBuddy free for 14 days. No hidden fees, cancel anytime.
Start Free Trial